Literature DB >> 31387157

Long-term clinical course and outcome of interstitial pneumonia with autoimmune features.

Ho Cheol Kim1, Joo Hee Lee1, Eun Jin Chae2, Joon Seon Song3, Jin Woo Song1.   

Abstract

BACKGROUND AND
OBJECTIVE: Idiopathic interstitial pneumonia (IIP) with autoimmune features that does not fulfil connective tissue disease (CTD) criteria has been recently defined as interstitial pneumonia with autoimmune features (IPAF). However, its long-term clinical course and outcome are poorly understood.
METHODS: We included consecutive patients diagnosed with IIP (n = 586) or CTD-related interstitial lung disease (CTD-ILD, n = 149). Some patients with IIP were reclassified as IPAF based on recent guidelines.
RESULTS: The median follow-up period was 45 months. Among the IIP patients, 109 (18.6%) were reclassified as IPAF. Compared to the non-IPAF-IIP group, the IPAF group had slower diffusing capacity of the lung for carbon monoxide (DLCO ) and total lung capacity declines, and more frequent CTD development during follow-up periods. The prognosis of the IPAF was better than that of the non-IPAF-IIP and similar to that of the CTD-ILD. IPAF was associated with better prognosis in the IIP cohort on univariate but not on multivariate analysis. Usual interstitial pneumonia (UIP) pattern, old age and low DLCO independently predicted mortality in the IPAF group.
CONCLUSION: Compared to the non-IPAF-IIP group, the IPAF group had slower lung function declines and more frequent CTD development during follow-up. Although the prognosis of IPAF group was better than that of non-IPAF-IIP group and similar to that of CTD-ILD group, it showed poor prognosis in patients with old age, UIP pattern, and low DLCO .
© 2019 Asian Pacific Society of Respirology.

Entities:  

Keywords:  connective tissue disease-associated interstitial lung disease; idiopathic interstitial pneumonia; interstitial pneumonia with autoimmune features; prognosis

Mesh:

Year:  2019        PMID: 31387157     DOI: 10.1111/resp.13665

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  6 in total

Review 1.  Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential.

Authors:  Marco Sebastiani; Paola Faverio; Andreina Manfredi; Giulia Cassone; Caterina Vacchi; Anna Stainer; Maria Rosa Pozzi; Carlo Salvarani; Alberto Pesci; Fabrizio Luppi
Journal:  Biomedicines       Date:  2020-12-26

2.  Lung fibrosis in autoimmune diseases and hypersensitivity: how to separate these from idiopathic pulmonary fibrosis.

Authors:  Helmut Popper; Elvira Stacher-Priehse; Luka Brcic; Andreas Nerlich
Journal:  Rheumatol Int       Date:  2021-10-04       Impact factor: 3.580

3.  Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.

Authors:  Kevin K Brown; Yoshikazu Inoue; Kevin R Flaherty; Fernando J Martinez; Vincent Cottin; Francesco Bonella; Stefania Cerri; Sonye K Danoff; Stephane Jouneau; Rainer-Georg Goeldner; Martin Schmidt; Susanne Stowasser; Rozsa Schlenker-Herceg; Athol U Wells
Journal:  Respirology       Date:  2022-02-27       Impact factor: 6.175

Review 4.  Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists.

Authors:  Hong Ki Min; Se-Hee Kim; Sang-Heon Lee; Hae-Rim Kim
Journal:  Korean J Intern Med       Date:  2021-02-08       Impact factor: 2.884

5.  Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases.

Authors:  Fernanda Hernandez-Gonzalez; Sergio Prieto-González; Pilar Brito-Zeron; Sandra Cuerpo; Marcelo Sanchez; Jose Ramirez; Carlos Agustí; Carmen María Lucena; Marina Paradela; Ignacio Grafia; Gerard Espinosa; Jacobo Sellares
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

6.  Systematic review and meta-analysis of the prognosis and prognostic factors of interstitial pneumonia with autoimmune features.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMJ Open       Date:  2019-12-11       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.